Biotechnologies - Model TruAB - Therapeutic Neutralizing Antibodies for SARS-CoV-2
From Drug Discovery
Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the disease and provide passive immunity to people who have recently been exposed to SARS-CoV-2.
-
Most popular related searches
Products Details
The immunoSEQ® T-MAP™ COVID offering provides tools for researchers to study the COVID-19 T-cell immune response, including detecting past SARS-CoV-2-specific immune response in research samples & the ability to track responses longitudinally.
With immunoSEQ T-MAP COVID researchers can:
- Detect past SARS-CoV-2-specific T-cell immune response with a simple positive/negative result in research samples & track responses longitudinally.
- Search our SARS-CoV-2-specific TCR database to determine if their samples show SARS-CoV-2-specific TCRs & the antigens to which these TCR responded.
- Study the T-cell immune response for vaccine research across COVID-19 variants. Map across >160K SARS-CoV-2-specific antigen-TCR sequence-level data.
- Dive into sequence, patient or population-level data. Determine TCR clones shared between cohorts & those that are public vs private clones.
Customer reviews
No reviews were found for Biotechnologies - Model TruAB - Therapeutic Neutralizing Antibodies for SARS-CoV-2. Be the first to review!